Glenmark Pharmaceuticals reaches agreement with Pfizer for Axitinib Tablets

22 Nov 2022 , 09:04 AM

Glenmark Pharmaceuticals Inc., USA (Glenmark) and Glenmark Pharmaceuticals have reached a settlement agreement with Pfizer Inc., PF Prism C.V., and PF Prism IMB B.V. (Pfizer) for Axitinib Tablets, 1 mg and 5 mg, the generic version of their Inlyta?1 Tablets, 1 mg and 5 mg. Glenmark had previously announced it received tentative approval by the United States Food & Drug Administration (USFDA) for their generic Axitinib Tablets, 1 mg and 5 mg on 30 November 2020. According to IQVIATM sales data for the 12&8208;month period ending September 2022, the Inlyta? Tablets, 1 mg and 5 mg market achieved annual sales of approximately $644.5 million. Powered by Capital Market – Live News